Partners Group invests in Forefront Dermatology
Context
Structured as a secondary institutional buyout, the definitive acquisition agreement formalizes the transfer of Forefront Dermatology from exiting sponsor OMERS Private Equity to the incoming global investment manager Partners Group AG. Announced in February 2022, the financial architecture of this corporate transaction values the targeted clinical network at an enterprise value of €1–10bn. Following the close of the transaction scheduled for the early second quarter of 2022, the existing executive leadership team and the affiliated network of medical physicians will explicitly retain an ownership stake in the newly recapitalized structure. Furthermore, the exiting sponsor OMERS Private Equity intends to strategically reinvest a portion of its proceeds to remain a minority shareholder alongside Partners Group AG. This divestiture concludes a highly successful six-year holding period for OMERS Private Equity, during which the pension fund arm supported the medical platform in doubling its geographic footprint and clinician base, ultimately generating a lucrative capital event for the 525,000 members of the OMERS pension plan under the strategic supervision of Global Head Michael Graham and Managing Director Mark Van Wart. To orchestrate this healthcare transaction, the selling consortium assembled an extensive advisory roster. OMERS Private Equity and Forefront Dermatology exclusively retained the investment banking firm Harris Williams to pilot the competitive financial auction, with Ernst & Young handling the specialized financial and accounting due diligence. Legal structuring and regulatory compliance for the sellers were jointly coordinated by the law firms Sidley Austin and McDermott Will & Emery. Conversely, the acquiring sponsor Partners Group AG secured buy-side financial advisory services from Deutsche Bank and comprehensive legal representation from Ropes & Gray.
The acquisition of Forefront Dermatology is part of the growth strategy of Partners Group, which already has several external growth operations under its belt, notably Atnorth in 2022.
-> Deep-dive in Healthcare & Pharma market trends
Target
Since its foundation in 2001 by Dr. Kenneth H. Katz under the initial name Dermatology Associates of Wisconsin, Forefront Dermatology operates as a specialized practice management network providing centralized operational infrastructure to clinical dermatology facilities. Headquartered in Manitowoc, Wisconsin, the medical organization coordinates a vast healthcare footprint encompassing over 80 clinics distributed across 11 Midwestern and Mid-Atlantic states. The corporate entity focuses on delivering administrative management, centralized support, and advanced information technology services to allow medical practitioners to concentrate exclusively on patient care. The clinical portfolio covers a broad spectrum of medical treatments, ranging from general and surgical dermatology to cosmetic procedures and specialized laboratory services. Renamed in 2014 to reflect its accelerated regional expansion, the enterprise relies on a substantial workforce comprising over 90 board-certified dermatologists, 130 dedicated corporate employees based at the headquarters, and more than 800 healthcare professionals and support staff.
Ent. Value
€1–10bn
Equity Value
[members only]
Multiples
EV / Revenue
4x–10x
EV / EBITDA
15x–25x
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with Forefront Dermatology
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 02/2016 | OMERS | FOREFRONT DERMATOLOGY | UNITED STATES | Outpatient Care |
Other operations with Partners Group
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 08/2026 | PARTNERS GROUP | AROMA-ZONE | FRANCE | Hygiene & Beauty Brands |
| 06/2025 | PARTNERS GROUP | MPM | UNITED KINGDOM | Pet Care |
| 10/2022 | PARTNERS GROUP | TELEPASS | ITALY | Fintech & Payments |
| 02/2022 | MONTAGU PRIVATE EQUITY / PARTNERS GROUP | HTL BIOTECHNOLOGY | FRANCE | CDMO |
| 01/2022 | PARTNERS GROUP | ATNORTH | ICELAND | Hosting / Datacenter |
| 11/2021 | PARTNERS GROUP | DIVERSITECH | UNITED STATES | Valves, Pumps & Taps |
| 07/2021 | PARTNERS GROUP | PHARMATHEN | GREECE | CDMO |
| 07/2020 | PARTNERS GROUP | ROVENSA | PORTUGAL | Specialty Chemicals |
| 01/2017 | PARTNERS GROUP / PSP INVESTMENTS | CERBA HEALTHCARE | FRANCE | Labs (Biology) |
Similar deals in Health Providers
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 06/2022 | EURAZEO | SEVETYS | FRANCE | Vet Clinics |
| 04/2022 | GROUPE BRUXELLES LAMBERT | AFFIDEA | NETHERLANDS | Radiology |
| 02/2022 | MEINE RADIOLOGIE | ALERIS - RADIOLOGY | SWEDEN | Radiology |
| 01/2022 | WREN HOUSE | VOYAGE CARE | UNITED KINGDOM | Nursing Homes |
| 12/2021 | RAMSAY HEALTH CARE | ELYSIUM HEALTHCARE | UNITED KINGDOM | Clinics / Hospitals |
| 12/2021 | VIVALTO PARTNERS / IK PARTNERS / MACSF / ARKEA CAPITAL / BNP PARIBAS DEVELOPPEMENT | VIVALTO SANTÉ | FRANCE | Clinics / Hospitals |
| 11/2021 | CERBA HEALTHCARE | LABEXA | FRANCE | Labs (Biology) |
| 10/2021 | IVC EVIDENSIA | VETONE | FRANCE | Vet Clinics |
| 10/2021 | ARES / BPIFRANCE | POINT VISION | FRANCE | Ophthalmology |
| 10/2021 | THE CRANEMERE GROUP | OUTPATIENT IMAGING AFFILIATES | UNITED STATES | Radiology |
REFERENCES
Valuation range: EV €1–10bn
Revenue range: €150–250M
EBITDA range: €50–100M
EV/Revenue range: 4x - 10x
EV/EBITDA range: 15x - 25x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Forefront Dermatology by Partners Group are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: forefront dermatology
FAQ
What transaction does this page cover?
How was the acquisition of Forefront Dermatology by Partners Group valued, and what multiples were paid?
What were Forefront Dermatology’s revenue and EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?